e-Therapeutics plc Immuno-Oncology Research Collaboration with iTeos (2180H)
05 Abril 2022 - 1:00AM
UK Regulatory
TIDMETX
RNS Number : 2180H
e-Therapeutics plc
05 April 2022
e-therapeutics plc
("e-therapeutics" or "the Company")
Immuno-Oncology Research Collaboration with iTeos
Therapeutics
Oxford, UK, 5 April 2022 - e -therapeutics plc (AIM: ETX; OTCQX:
ETXPF), a specialist in computational drug discovery with a focus
on developing RNA interference ("RNAi") therapeutics, announces
that it has entered into a research collaboration agreement with
iTeos Therapeutics, Inc. ("iTeos", Nasdaq: ITOS), a clinical-stage
biopharmaceutical company pioneering the discovery and development
of a new generation of highly differentiated immuno-oncology
therapeutics for patients. The collaboration will focus on the
discovery of novel therapeutic approaches and targets in
immuno-oncology. e-therapeutics will remain free to explore
additional collaborations in the space.
Under the terms of the agreement, e-therapeutics will receive
upfront and near-term cash payments material to the revenue of the
Company. The Company is also eligible to receive undisclosed
milestone payments through pre-clinical and clinical development,
in addition to regulatory milestones per programme.
The collaboration will combine key expertise from both
companies, including e-therapeutics' computational platform and
iTeos' proprietary assays. iTeos is a leader in the immuno-oncology
space developing next-generation therapies for patients with
cancer. e-therapeutics' computational platform and in silico
predictions have been experimentally validated across multiple
therapeutic areas (including in immuno-oncology), demonstrating its
ability to reproducibly assess millions of therapeutic hypotheses,
gain insights into lesser-known mechanistic disease processes and
identify therapeutic interventions with a higher probability of
success than standard drug discovery processes. This translates
into a more efficient drug discovery process with greater scope for
novelty, as well as significant time and cost savings.
Ali Mortazavi, Chief Executive Officer of e-therapeutics,
commented:
"We are extremely pleased to partner with iTeos to help identify
highly differentiated immuno-oncology medicines for patients. We
believe that our computational platform can discover novel
therapeutic approaches for iTeos to prosecute in a hugely promising
area of cancer treatment. This collaboration provides further
validation of the value of our network-driven, disease agnostic
computational platform, which we will continue to leverage as we
build our in-house RNAi based pipeline."
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulations (EU) No. 596/2014 which has been
incorporated into UK law by the European Union (Withdrawal) Act
2018.
Enquiries:
e-therapeutics plc
Ali Mortazavi, CEO Tel: +44 (0)1993 883
Laura Roca-Alonso, CBO 125
www.etherapeutics.co.uk
SP Angel Corporate Finance LLP Tel: +44(0)20 3470
0470
Nominated Adviser and Broker
Matthew Johnson/Caroline Rowe (Corporate
Finance)
Vadim Alexandre/Rob Rees (Corporate
Broking)
About iTeos Therapeutics, Inc.
iTeos Therapeutics is a clinical-stage biopharmaceutical company
pioneering the discovery and development of a new generation of
highly differentiated immuno-oncology therapeutics for patients.
iTeos Therapeutics leverages its deep understanding of tumour
immunology and immunosuppressive pathways to design novel product
candidates with the potential to fully restore the immune response
against cancer. The Company's innovative pipeline includes two
clinical-stage programs targeting novel, validated immuno-oncology
pathways designed with optimized pharmacologic properties for
improved clinical outcomes. The first antibody product candidate,
EOS-448, is a high affinity, potent, anti-TIGIT antibody with a
functional Fc domain, designed to enhance the anti-tumour response
through a multifaceted immune modulatory mechanism, currently
progressing in multiple indications in collaboration with GSK. The
Company is also advancing inupadenant, a next-generation adenosine
A2A receptor antagonist tailored to overcome cancer
immunosuppression into proof-of concept trials in several
indications following encouraging single-agent activity in Phase 1.
iTeos Therapeutics is headquartered in Watertown, MA with a
research center in Gosselies, Belgium.
About e-therapeutics plc
e-therapeutics plc is a UK-based company integrating
computational power and biology to accelerate the discovery of
life-transforming medicines. The Company has developed and
validated a powerful, disease and modality agnostic computational
approach to drug discovery, leveraging its industry-leading
expertise in network biology to fully capture and interrogate human
disease complexity.
The Company's multi-disciplinary team builds computational
models of biological functions to transform the search for new
medicines, interventions, mechanisms and genetic support. Its
biology-led in silico laboratory enables rapid hypothesis
generation and phenotypic screening of millions of compounds
leading to 100-1000x higher hit rates in the wet lab and successful
mode of action elucidation. Novel targets can also be identified,
prioritised and assessed. Harnessing internal target gene
discoveries, e-therapeutics is currently building an in-house
pipeline of RNAi based medicines, using its proprietary
GalNAc-siRNA technology.
e-therapeutics has deployed and validated its disease-agnostic
computational drug discovery platform both in house and with
partners, including Novo Nordisk, Galapagos NV and a US-based, top
5 pharmaceutical company.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RESZZGGDVDNGZZM
(END) Dow Jones Newswires
April 05, 2022 02:00 ET (06:00 GMT)
E-therapeutics (LSE:ETX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
E-therapeutics (LSE:ETX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024